The Most Dangerous Slide in Healthtech Is the One Full of Unicorns

Hologic’s $76-per-share cash payment came with a telling qualifier: up to $3 more, tied to future results.

When Blackstone and TPG completed the transaction on April 7, shareholders were entitled to $76 per share in cash, plus a contingent right to as much as $3 more. Those additional dollars depended on the breast-health business reaching specified revenue goals in fiscal 2026 and 2027. Even at this scale, some of the price remained attached to work not yet done. Hologic closing release

I find that more instructive than the headline.

A headline gives us an outcome to admire. The terms tell us what somebody was prepared to pay for—and what still required proof.

That distinction is easily lost in an early-stage pitch. A slide of successful companies appears, their acquisition prices neatly arranged beneath their logos, and a possibility quietly becomes an expectation. The category produced a large exit. Therefore, the category should produce another. Therefore, this company deserves to be financed.

Several essential questions have disappeared between those sentences.

What did the buyer actually need? How long did the company take to build it? Who financed the difficult years? How much ownership survived? And which part of the value belonged to the invention, rather than the machinery required to make it useful?

I’m interested in the detail that complicates the story. At Succedia Ventures, I want that instinct to serve a more consequential purpose: distinguishing a business that matters from an investment that makes sense.

Those are related judgments. They are not interchangeable.

This letter revisits six transactions through that distinction. It also explains how the questions they raise are shaping Succedia’s work—and what we are beginning to learn from the community around it.

A recovery, viewed from the wrong end of the telescope

The first-half funding numbers offer a warning about averages.

U.S. digital-health companies raised $7.4 billion across 244 deals in H1 2026, according to Rock Health. Twenty financings of at least $100 million took 45% of the capital. Funding was higher than a year earlier, on almost the same number of deals. These are first-half figures, not a completed Q3 funding total. Rock Health H1 overview

From a distance, that looks like a recovery. From the perspective of a founder outside those large rounds, the experience may be quite different.

My reading is that concentration makes the sequence of proof more important. The relevant question is not simply whether a company can raise its next round. It is whether the money available now can buy a result that changes the next investor’s assessment.

An elegant financing can postpone that confrontation. A disciplined one brings it forward.

I would rather see a company reach the experiment that could invalidate its central assumption than spend another year making the assumption more presentable. A larger round can be valuable, but size alone does not tell us whether uncertainty has been reduced or merely funded for longer.

This is also why I resist borrowing confidence from mature-company acquisitions. A buyer purchasing an established distribution network is making a different decision from a seed investor financing the attempt to build one.

The exits belong in the research. They do not belong in the forecast without considerably more work.

The map: what earned attention, what remains open

This transaction map includes a private-company financing, strategic acquisitions and buyouts of mature businesses. Each reveals a different part of the investment question.

The purpose is to distinguish the public evidence from the questions an investor must still answer.

The questions below are my research questions. They are not findings that the named companies have failed to solve these problems.

Snorkel AI

Announced $350 million in Series E financing at a $3.5 billion valuation on September 22. The company reported a $375 million annualized revenue run rate—not a completed year of recognized revenue. Snorkel CEO announcement

The diligence question: Does expanding demand leave behind increasingly reusable technology, or require proportionately more expert labor?

Tempus / Personalis

Announced July 20 at $1.5 billion enterprise value, net of Tempus’ existing ownership interest. The announcement anticipated closing in late 2026 or early 2027; it is treated here as an agreement, not a completed acquisition. Tempus announcement

The diligence question: What must connect a more sensitive cancer measurement to a clinical decision, a practical next step and payment?

Hologic / Blackstone and TPG

Announced in October 2025 at up to $18.3 billion enterprise value; completed April 7, 2026, with part of the consideration contingent on future revenue milestones. Hologic transaction announcement

The diligence question: Where can a new women’s-health business meet an underserved need without recreating an incumbent’s entire commercial system?

Integer / KKR

Announced August 3 at approximately $5.7 billion enterprise value for a medical-device contract development and manufacturing business. The announcement expected closing by year-end, subject to conditions. Integer transaction announcement

The diligence question: Which development, quality or manufacturing problem can a young company own without inheriting the capital requirements of the whole network?

I-MED / Jardine Matheson

Announced at A$3.4 billion enterprise value—approximately US$2.4 billion at announcement; completed September 30. The announced network comprised 215 clinics and more than seven million annual procedures. Jardine transaction announcement

The diligence question: When better technology enters established clinical distribution, who retains the economics?

Biocare Medical / Agilent

A $950 million acquisition, measured as net cash consideration, closed June 24; completion was announced June 25. It extended Agilent’s pathology capabilities across instruments, reagents and related workflows. Agilent acquisition filing

The diligence question: What still needs to connect reliable specimen preparation and interpretation with the decisions that follow?

These figures should be examined individually.

Adding a private-company financing valuation to acquisition enterprise values would produce an impressive number and a poor argument. Even among acquisitions, contingent consideration, existing ownership, debt and currency conversion affect what the headline means.

What interests me is the pattern beneath these different transactions: buyers and investors are assigning value to difficult data, measurement, specialized production, clinical distribution and the systems surrounding a decision.

That is a reason to investigate. It is not yet a reason to invest.

The arrow is the business

Consider the simplest diagram in a healthcare presentation:

Measurement → interpretation → decision → action.

The boxes have names, product screenshots and technical explanations. The arrows usually receive less attention.

I suspect they deserve more.

Tempus and Personalis illustrate why. Their proposed combination follows a commercial relationship established in November 2023. It would bring Personalis’ molecular-residual-disease testing closer to Tempus’ multimodal data, AI and commercial capabilities. The strategic proposition is broader than a test: it concerns the connections across cancer monitoring and care. Tempus announcement

My interest begins at those connections.

Imagine a company producing a more informative result. Before assuming it has created a stronger business, I would follow that result through the customer’s day. Who receives it? What evidence persuades that person to act? Who takes responsibility for the next step? What happens when the result is ambiguous? Where does the payment come from?

These are the questions hidden inside the arrow.

A business can be technically excellent at one end of the diagram and commercially dependent at the other. That dependence may be a sensible partnership. It may also determine the speed of adoption, the customer relationship and the margin left for the inventor.

This is one reason I spend time on what happens after a promising result. A workflow, a coordination system or a method of making evidence usable may appear less original than the measurement itself. Yet it may decide whether the measurement reaches everyday care.

There is an important restraint here. An unresolved handoff is not automatically a market. The obstacle may be weak evidence, a missing budget or a task an incumbent can absorb with a modest product change.

The founder I want to meet can explain why this particular handoff is painful, who will pay to improve it and why the proposed company—not merely the industry—can capture the value.

Better data can conceal an expensive business

Snorkel’s financing offers a different version of the same question. Its announcement describes a business combining expert participation with AI-assisted data development and evaluation. It reports substantial growth since launching its data-as-a-service offering. That is company-reported evidence of demand; it does not, by itself, settle the economics of producing the next unit of useful data. Snorkel financing release

I would not dismiss expert-intensive work because it involves people. I would ask what the business gets to keep after the people have done it.

For a hypothetical healthcare-data company, that means following a single project carefully. How was the information obtained? What rights govern its use? How were disagreements between specialists resolved? Which parts of the process can improve the next engagement, and which must be repeated from the beginning?

A company may accumulate a valuable system through that work. Or it may deliver excellent projects while continually rebuilding the capability that made the previous one possible.

The revenue can look similar before the underlying difference becomes obvious.

This leads to the question we put at the center of Succedia’s September positioning work:

If the AI inside your product became ten times cheaper, what would become more valuable about your company?

It is a hypothetical stress test, not a prediction about model prices.

A useful answer might be a difficult measurement, an outcome-linked dataset, a well-used workflow or a commercial relationship through which better intelligence can immediately reach a customer.

The answer may also be uncomfortable: much of the product becomes easier to reproduce.

That is worth discovering while a company still has the freedom to change.

A company can be narrow without being small-minded

The fear of becoming somebody else’s feature can send a founder in the wrong direction.

There is a temptation to respond by owning more: the data, the interpretation, the workflow, the channel, eventually the entire platform. Ambition fills the diagram faster than capital fills the bank account.

I would rather ask which capability the business cannot afford to lose control of.

Integer and Biocare are useful reminders that important healthcare businesses can sit behind someone else’s product or clinical relationship. Integer develops and manufactures medical devices for customers. Biocare supplies specialized pathology capabilities that now sit inside Agilent’s broader portfolio. Their transactions concern valuable positions within larger systems, not ownership of every layer.

For an early company, the task is to identify a narrow capability with enough consequence that customers cannot casually substitute it.

Then the less glamorous questions begin. How concentrated are the customers? How difficult is replacement in practice? How much service does each deployment require? Can the company raise prices without losing its place? What capital must be committed before delivery becomes dependable?

Calling something “infrastructure” does not answer those questions.

Nor does being necessary guarantee attractive economics. A supplier can be important to its customer and still negotiate from a weak position. A product can save substantial money while its creator retains very little of the saving.

That is the distinction I want our underwriting to keep visible: creating value for the system and retaining value for the company.

Distribution has its own ideas about who should get paid

I-MED’s acquisition completed on the final day of Q3. Its clinical network gives the transaction a different character from a software financing: this is an established organization through which technology can potentially reach repeated, real-world use. I-MED closing confirmation

For a startup, access to that kind of distribution could change the business. It could also change the balance of power against it.

The questions I would ask concern the relationship after the introduction has been made. Does the startup retain access to the customer? Can it learn from deployment? Are its rights and economics preserved? Can it serve another network? What prevents its partner from substituting a competing supplier?

The word partnership does very little work until those questions are answered.

This matters to the way I think about trust as well. A trusted relationship may make a difficult conversation possible. It should not spare either party the need to have it.

Good intentions do not resolve unclear rights. Familiarity does not establish clinical utility. A warm introduction does not determine who gets paid.

For me, the purpose of trust is to make examination more candid.

That is a considerably more useful investment asset than an agreement never to disagree.

What this has changed at Succedia

We refined our focus in September into four verbs: Measure, Connect, Act and Translate.

Measure covers diagnostics and biomarkers that produce useful signals. Connect concerns data and AI infrastructure, including the rights and context that make information usable. Act addresses the workflows through which evidence enters care. Translate concerns defensible science and its practical route to adoption.

Together, they describe what we mean by healthspan intelligence infrastructure.

The wording has a practical purpose. It makes a founder explain a job rather than claim a category. What is being measured? What becomes possible once the data is connected? Whose decision changes? What must happen before the science becomes a business?

It also makes our exclusions clearer. An attractive healthcare company need not fit Succedia. I do not want the definition of infrastructure to expand every time an interesting opportunity arrives.

I want scientific and operating expertise to contribute to specific work, case by case. A community speaker is not automatically a fund adviser or investment-committee member.

What I want from relevant expertise is a better objection.

A clinician who can explain why a result would not change practice. An operator who can identify an implementation cost omitted from the model. A commercial specialist who can distinguish enthusiasm from a budget. An IP specialist who can show where apparent protection does—and does not—matter.

An impressive biography can earn someone our attention. What they help us see should determine their contribution.

The useful part of the room happens afterward

For Legacy Lounge, I want the operating record to be specific: the purpose of a conversation, the next step agreed and what actually happened afterward.

An introduction, a completed conversation, a customer discussion and a sale represent different stages of progress. I want to follow those stages carefully rather than allow a promising next step to become a claimed outcome.

The community’s usefulness should become visible in that record. It should remain separate from investment performance.

A beautiful room is not a diligence method

I enjoy the human work of hosting: choosing a setting people want to stay in, allowing dinner to run beyond the formal conversation, leaving enough space for somebody to ask the question they had been holding back.

There is a reason to care about that experience. There is also a reason to be wary of it.

Good company can make an argument feel better than it is. Repeated contact can make a person familiar before their assumptions have been examined. A fluent founder can occupy more of the room than a less polished scientist with stronger evidence.

I want our gatherings to bring those people into contact without confusing warmth with verification.

For prospective partners, the standard is similarly concrete. Relevant expertise, practical services and thoughtful follow-through should make the community more useful. Commercial participation remains separate from investment consideration; paid membership is not a requirement for a founder to be considered by Succedia.

For an LP, the proposition is that sustained relationships may improve access to context, references and useful disagreement. Whether that develops into a durable investment advantage has to be demonstrated over time.

A full calendar does not settle the question.

The case against my own case

There are several ways this thesis could disappoint.

An incumbent could bundle the capability we considered scarce. A dataset could prove less differentiated than it first appeared, or its rights less durable. A workflow could remain expensive to implement at every customer. The product that looks indispensable from the seller’s side could be something the buyer would gladly replace.

A strategic acquisition could also be rational for a buyer and a poor guide to venture returns. Financing needs, dilution, time and entry price still have to be accounted for. The headline will not do that arithmetic for us.

There is a final risk worth admitting: looking beyond the model can become its own fashion.

Sometimes the scientific or technical breakthrough really is the hard part. Sometimes a superior model is the source of advantage. A preference for infrastructure should not become a reason to underestimate either.

I want our thesis to help us choose better questions—and remain open to answers that change it.

What I want Q4 to prove

For each business, I want to identify the next piece of evidence that could change the investment decision: a result that affects clinical practice, a deployment that becomes easier to repeat, a customer relationship with durable rights, or economics that improve as use grows.

Then I want to understand the cost and time required to earn that evidence. Entry price, financing needs, dilution and the likely path to liquidity belong in the same discussion.

For LPs evaluating a manager, my question is:

Which evidence would change the investment decision—and can the next financing buy it?

That is the work I want Succedia’s healthspan infrastructure thesis to guide. The transactions in this letter help locate the questions. The answers still have to come from the company.

If you are building, operating or evaluating a business in this space, I would love to compare notes on the evidence you are working to establish next.

This letter presents public transaction facts and original analysis. Named companies are research examples; their inclusion does not imply a Succedia investment, affiliation or endorsement. The tenfold AI-cost change is a hypothetical stress test. Figures use their stated valuation bases and should not be added together.